Phase I study of GSK461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 17, Issue 10, 2011, Pages 3420-3430

  Olmos, David ^a   Barker, Douglas ^b   Sharma, Rohini ^b   Brunetto, Andre T ^a   Yap, Timothy A ^a   Taegtmeyer, Anne B ^b   Barriuso, Jorge ^a   Medani, Hanine ^b   Degenhardt, Yan Y ^c   Allred, Alicia J ^c   Smith, Deborah A ^c   Murray, Sharon C ^c   Lampkin, Thomas A ^c   Dar, Mohammed M ^c   Wilson, Richard ^d   De Bono, Johann S ^a   Blagden, Sarah P ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN SULFOBUTYL ETHER; DALTEPARIN; ENOXAPARIN; GSK 461364; HISTONE H3; KI 67 ANTIGEN; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; TINZAPARIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANUS CANCER; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CONTROL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CARCINOMA; DIARRHEA; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; ESOPHAGUS CANCER; FEMALE; HISTONE PHOSPHORYLATION; HUMAN; INJECTION SITE REACTION; KIDNEY CANCER; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY ADENOCARCINOMA; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLEURA MESOTHELIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECTUM CARCINOMA; RETROPERITONEAL CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; THORAX PAIN; THROMBOCYTOPENIA; TUMOR BIOPSY; VENOUS THROMBOEMBOLISM;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BINDING, COMPETITIVE; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SUBSTRATE SPECIFICITY; THIOPHENES;

EID: 79956014825     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2946     Document Type: Article

References (25)

1. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006;5:853-64. (Pubitemid 44145580)
2. Budirahardja Y, Gonczy P. PLK-1 asymmetry contributes to asynchronous cell division of C. elegans embryos. Development 2008;135:1303-13. (Pubitemid 351622474)
3. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20:650-60.
4. Dias SS, Hogan C, Ochocka AM, Meek DW. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett 2009;583:3543-8.
5. Holtrich U, Wolf G, Bräuninger A, Karn T, Böhme B, Ruvbsamen-Waigmann H, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A 1994;91:1736-40. (Pubitemid 24080280)
6. Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Köbel M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90:815-21. (Pubitemid 38406592)
7. Feng YB, Lin DC, Shi ZZ, Wang XC, Shen XM, Zhang Y, et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009;124:578-88.
8. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 1997;234:397-405. (Pubitemid 27243915)
9. Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559-70.
10. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 2010;16:384-9.
11. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009;69:6969-77.
12. Laquerre S, Sung C-M, Gilmartin A, et al. A potent and selective Pololike kinase 1 (Plk1) inhibitor (GSK461364) induces cell cycle arrest and growth inhibition of cancer cell [abstract]. Proceedings of the AACR Annual Meeting; April 14-18; Los Angeles, CA. Philadelphia, PA: AACR; 2007. Abstract 5389.
13. Sutton D, Diamond M, Faucette L, et al. Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models [abstract]. Proceedings of the AACR Annual Meeting ; April 14-18; Los Angeles, CA. Philadelphia, PA: AACR; 2007. Abstract 5388.
14. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
17. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904. (Pubitemid 39383039)
18. Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20:27-33.
19. 2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60.
20. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-7.
21. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
22. Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009;27:4895-901.
23. Stein PD, Beemath A, Meyers FA, Skaf E, Sanchez J, Olson RE, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 2006;119:60-8. (Pubitemid 43117468)
24. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-85.
25. Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, et al. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 2008;68:4077-85.